CYTOSORBENTS ($CTSO) posted quarterly earnings results for Q1 2026 on Wednesday, May 13th. The company reported earnings of -$0.08 per share, missing estimates of -$0.06 by $0.02. The company also reported revenue of $8,860,000, missing estimates of $9,550,260 by $-690,260.
You can see Quiver Quantitative's $CTSO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CYTOSORBENTS Hedge Fund Activity
We have seen 26 institutional investors add shares of CYTOSORBENTS stock to their portfolio, and 17 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PATHSTONE HOLDINGS, LLC added 499,955 shares (+inf%) to their portfolio in Q4 2025, for an estimated $319,571
- CM MANAGEMENT, LLC added 188,372 shares (+14.6%) to their portfolio in Q4 2025, for an estimated $120,407
- AVENIR CORP added 147,261 shares (+2.9%) to their portfolio in Q4 2025, for an estimated $94,129
- SKYLANDS CAPITAL, LLC removed 147,017 shares (-7.9%) from their portfolio in Q1 2026, for an estimated $83,255
- SARGENT INVESTMENT GROUP, LLC removed 126,700 shares (-17.2%) from their portfolio in Q4 2025, for an estimated $80,986
- CITADEL ADVISORS LLC added 83,589 shares (+127.2%) to their portfolio in Q4 2025, for an estimated $53,430
- GSA CAPITAL PARTNERS LLP added 36,157 shares (+32.2%) to their portfolio in Q4 2025, for an estimated $23,111
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
